{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T21:40:31Z","timestamp":1722030031266},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:00:00Z","timestamp":1718928000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bundesgesundheitsbl"],"published-print":{"date-parts":[[2024,8]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Die Pr\u00e4valenz von Herz-Kreislauf-Erkrankungen steigt mit zunehmenden Alter an. H\u00e4ufige Symptome sind Atemnot, Brustschmerzen, Schwindel oder Synkopen, welche die Fahreignung beeinflussen k\u00f6nnen. Aufgrund einer zunehmenden Anzahl an Privatfahrer:innen \u00fcber 65\u00a0Jahren und einer steigenden Pr\u00e4valenz kardiovaskul\u00e4rer Erkrankungen r\u00fccken Fragestellungen zur Einschr\u00e4nkung der Fahreignung von kardiologischen Patient:innen zunehmend in den klinischen Vordergrund. Dieser Artikel soll aktuelle Empfehlungen zur Fahreignung im Kontext kardiovaskul\u00e4rer Erkrankungen zusammenfassen. Die Grundlage der Vorgaben stellen die Anlage\u00a04 der Fahrerlaubnisverordnung, die Begutachtungsleitlinie der Bundesanstalt f\u00fcr Stra\u00dfenwesen sowie die Leitlinien der Deutschen Gesellschaft f\u00fcr Kardiologie zur Fahreignung dar. Originalliteratur zu diesem Thema ist nur begrenzt vorhanden.<\/jats:p><jats:p>Mit Betonung auf eine individualisierte Bewertung werden klare Vorgaben f\u00fcr die Fahreignung bei kardialen Erkrankungen bzw. deren Symptomen oder Behandlungen formuliert. Die resultierenden Beeintr\u00e4chtigungen k\u00f6nnen von wenigen Wochen bis hin zur generellen Aufhebung einer Fahreignung ausfallen. F\u00fchrenden Einfluss auf die Bewertung der Fahreignung nehmen unabh\u00e4ngig von der kardialen Erkrankung die Symptomatik und die Wahrscheinlichkeit f\u00fcr einen pl\u00f6tzlichen Bewusstseinsverlust ein. Regelm\u00e4\u00dfige Untersuchungen sowie differenzierte Beurteilungen durch medizinisches Fachpersonal sind Voraussetzung f\u00fcr den Erhalt der Fahreignung.<\/jats:p><jats:p>Die Fahreignung \u00e4lterer Privatfahrer:innen stellt ein bedeutendes und praxisrelevantes Thema in der Kardiologie dar. Aktuelle Richtlinien unterst\u00fctzen die behandelnden \u00c4rzt:innen entsprechende Empfehlungen auszusprechen.<\/jats:p>","DOI":"10.1007\/s00103-024-03912-7","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T14:02:57Z","timestamp":1718978577000},"page":"896-902","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Einfluss kardiovaskul\u00e4rer Erkrankungen auf die Fahreignung:\u00a0Mobilit\u00e4tseinschr\u00e4nkungen\u00a0im\u00a0Alter","Impact of cardiovascular diseases on fitness to drive: mobility limitations in the elderly"],"prefix":"10.1007","volume":"67","author":[{"given":"Jan","family":"Rie\u00df","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niklas","family":"Schenker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian J.","family":"Brunner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tobias","family":"T\u00f6nnis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,6,21]]},"reference":[{"key":"3912_CR1","first-page":"2009","volume":"113","author":"C Dornquast","year":"2016","unstructured":"Dornquast\u00a0C, Kroll\u00a0LE, Neuhauser\u00a0HK, Willich\u00a0SN, Reinhold\u00a0T, Busch\u00a0MA (2016) Regional differences in the prevalence of cardiovascular disease. Dtsch \u00c4rztebl Int 113:2009\u20132012","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"3912_CR2","unstructured":"Ross D, Simpson A, Dorian P et\u00a0al (2003) Assessment of the cardiac patient for fitness to drive and fly\u2014Final report. Can Cardiovasc Soc Consens Conf: 1\u2013111"},{"issue":"38","key":"3912_CR3","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","volume":"44","author":"RA Byrne","year":"2023","unstructured":"Byrne\u00a0RA, Rossello\u00a0X, Coughlan\u00a0JJ et\u00a0al (2023) 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart\u00a0J 44(38):3720\u20133826","journal-title":"Eur Heart J"},{"key":"3912_CR4","unstructured":"Gr\u00e4cmann N, Albrecht M (2022) Begutachtungsleitlinien zur Kraftfahreignung. 2021(11):1\u2013139"},{"key":"3912_CR5","volume-title":"Fahreignung bei kardiovaskul\u00e4ren Erkrankungen \u2013 DGK Pocket Guideline","author":"HH Klein","year":"2023","unstructured":"Klein\u00a0HH, Eckardt\u00a0L, Perings\u00a0C (2023) Fahreignung bei kardiovaskul\u00e4ren Erkrankungen \u2013 DGK Pocket Guideline"},{"issue":"6","key":"3912_CR6","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/j.amjcard.2011.10.043","volume":"109","author":"RH Mehta","year":"2012","unstructured":"Mehta\u00a0RH, Yu\u00a0J, Piccini\u00a0JP et\u00a0al (2012) Prognostic significance of postprocedural sustained ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention (from the HORIZONS-AMI trial). Am J Cardiol 109(6):805\u2013812","journal-title":"Am J Cardiol"},{"key":"3912_CR7","unstructured":"Anlage\u00a04 FeV \u2013 Einzelnorm. https:\/\/www.gesetze-im-internet.de\/fev_2010\/anlage_4.html. Zugegriffen: 07-Feb-2024"},{"issue":"4","key":"3912_CR8","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/s41581-019-0244-2","volume":"16","author":"KT Mills","year":"2020","unstructured":"Mills\u00a0KT, Stefanescu\u00a0A, He\u00a0J (2020) The global epidemiology of hypertension. Nat Rev Nephrol 16(4):223\u2013237","journal-title":"Nat Rev Nephrol"},{"issue":"4","key":"3912_CR9","first-page":"e29","volume":"131","author":"D Mozaffarian","year":"2015","unstructured":"Mozaffarian\u00a0D, Benjamin\u00a0EJ, Go\u00a0AS et\u00a0al (2015) Heart disease and stroke statistics-2015 update : a\u00a0report from the American Heart Association. Circulation 131(4):e29","journal-title":"Circulation"},{"key":"3912_CR10","unstructured":"Medical standards for licensing | Austroads. https:\/\/austroads.com.au\/publications\/assessing-fitness-to-drive\/ap-g56\/cardiovascular-conditions\/medical-standards-for-licensing-1#vavular. Zugegriffen: 07-Feb-2024"},{"issue":"4","key":"3912_CR11","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s12181-019-0319-0","volume":"13","author":"W von Scheidt","year":"2019","unstructured":"von Scheidt\u00a0W, Bosch\u00a0R, Klingenheben\u00a0T et\u00a0al (2019) Manual on diagnosis and treatment of syncope. Kardiologe 13(4):198\u2013215","journal-title":"Kardiologe"},{"key":"3912_CR12","unstructured":"Guerra PG, Simpson CS, Van Spall HGC et\u00a0al (2023) Canadian cardiovascular society 2023 guidelines on the fitness to drive. Can J Cardiol: 1\u201324"},{"key":"3912_CR13","unstructured":"GOV (2021) Cardiovascular disorders: assessing fitness to drive\u2014GOV.UK. https:\/\/www.gov.uk\/guidance\/cardiovascular-disorders-assessing-fitness-to-drive#long-qt-syndrome---all-cases-of-long-qt-syndrome-must-notify-dvla. Zugegriffen: 06-Feb-2024"},{"issue":"40","key":"3912_CR14","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","volume":"43","author":"K Zeppenfeld","year":"2022","unstructured":"Zeppenfeld\u00a0K, Tfelt-Hansen\u00a0J, De Riva\u00a0M et\u00a0al (2022) 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: developed by the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart\u00a0J 43(40):3997\u20134126","journal-title":"Eur Heart J"},{"key":"3912_CR15","first-page":"253","volume-title":"The criteria committee for the New York heart association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels","author":"New York Heart Association","year":"1994","unstructured":"New York Heart Association (1994) The criteria committee for the New York heart association. Nomenclature and criteria for diagnosis of diseases of the heart and great vessels, 9.\u00a0Aufl. Little, Brown, Boston, S\u00a0253\u2013255","edition":"9"},{"issue":"6","key":"3912_CR16","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1093\/eurheartj\/ehaa1012","volume":"42","author":"J Bauersachs","year":"2021","unstructured":"Bauersachs\u00a0J (2021) Heart failure drug treatment: the fantastic four. Eur Heart\u00a0J 42(6):681\u2013683","journal-title":"Eur Heart J"},{"issue":"39","key":"3912_CR17","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","volume":"35","author":"JL Zamorano","year":"2014","unstructured":"Zamorano\u00a0JL, Anastasakis\u00a0A, Borger\u00a0MA et\u00a0al (2014) 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy: The task force for the diagnosis and management of hypertrophic cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart\u00a0J 35(39):2733\u20132779","journal-title":"Eur Heart J"},{"issue":"32","key":"3912_CR18","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1093\/eurheartj\/ehac180","volume":"43","author":"J Cadrin-Tourigny","year":"2022","unstructured":"Cadrin-Tourigny\u00a0J, Bosman\u00a0LP, Nozza\u00a0A et\u00a0al (2022) A\u00a0new prediction model for ventricular arrhythmias in arrhythmogenic right ventricular cardiomyopathy. Eur Heart\u00a0J 43(32):E1\u2013E9","journal-title":"Eur Heart J"}],"container-title":["Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-024-03912-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00103-024-03912-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00103-024-03912-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,26]],"date-time":"2024-07-26T21:05:54Z","timestamp":1722027954000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00103-024-03912-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,21]]},"references-count":18,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["3912"],"URL":"https:\/\/doi.org\/10.1007\/s00103-024-03912-7","relation":{},"ISSN":["1436-9990","1437-1588"],"issn-type":[{"value":"1436-9990","type":"print"},{"value":"1437-1588","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,21]]},"assertion":[{"value":"12 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"N.\u00a0Schenker gibt an, nichtfinanzielle F\u00f6rderung von Johnson & Johnson erhalten zu haben, au\u00dferhalb der eingereichten Arbeit. F.J.\u00a0Brunner berichtet \u00fcber F\u00f6rdermittel von Daiichi Sankyo, Novartis, Pfizer und Sanofi, nichtfinanzielle Unterst\u00fctzung von Abbott, ASAHI INTECC und Inari Medical sowie Honorare von Amgen, Daiichi Sankyo und Novartis au\u00dferhalb der eingereichten Arbeit. T.\u00a0T\u00f6nnis ist beratend t\u00e4tig f\u00fcr Medtronic, Boston Scientific und Pfizer. J.\u00a0Rie\u00df gibt an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"F\u00fcr diesen Beitrag wurden von den Autor\/-innen keine Studien an Menschen oder Tieren durchgef\u00fchrt. F\u00fcr die aufgef\u00fchrten Studien gelten die jeweils dort angegebenen ethischen Richtlinien.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}